Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

infliximab Injection [Inflectra]

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in… Expand
Is this relevant?
2018
2018
ABSTRACT Background: To describe the uptake and system-level effects of the introduction of biosimilars in a setting without… Expand
Is this relevant?
2017
2017
Introduction The biosimilar product Inflectra® has been approved by the European Medicine Agency (EMA) for the same indications… Expand
  • table I
  • table II
  • figure 1
  • figure 2
  • table III
Is this relevant?
2017
2017
Background Infliximab ('Remicade') has been authorized in the EU since 1999. It has a license for use in major rheumatic diseases… Expand
Is this relevant?
2017
2016
2016
ABSTRACT In this study, we demonstrate the utility of ultra-performance liquid chromatography coupled to mass spectrometry (MS… Expand
Is this relevant?
2016
2016
The approval of infliximab biosimilars Remsima™ and Inflectra™ (CT-P13) for patients with inflammatory bowel disease (IBD) is a… Expand
Is this relevant?
Review
2015
Review
2015
Introduction: Biosimilars are biologic products that receive authorization based on an abbreviated regulatory application… Expand
Is this relevant?
Review
2014
Review
2014
Biologics have revolutionized several areas of medical therapeutics, and dozens of them are used by millions of patients… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
In a defining moment for the European Medicines Agency (EMA) and the biopharmaceutical industry, on June 27, 2013 EMA’s Committee… Expand
Is this relevant?